International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)

What this Trial Is About

Dengue fever is a viral infection spread by Aedes mosquitoes and is a major health concern in tropical and subtropical areas. About 20-30% of people with symptoms develop Dengue Hemorrhagic Fever (DHF), which causes problems with blood clotting and increases bleeding risk. Individuals with congenital bleeding disorders (CBDs), such as hemophilia and von Willebrand disease, may be especially vulnerable to bleeding complications during dengue infection. This research aims to establish a registry to collect data on dengue infections in people with CBDs to better understand bleeding risks, treatments, and outcomes. The study is an international, multicenter observational registry that includes both retrospective data from January 2015 to December 2025 and prospective data collection. It gathers detailed information on individuals with CBDs diagnosed with dengue infection based on WHO criteria. Data collected includes clinical presentation, severity of bleeding, use of replacement therapy, and outcomes such as recovery or complications. The registry uses the REDCap system to standardize data collection across participating hospitals. Participants diagnosed with CBDs and dengue infection will have their medical information recorded, including age, sex, type of bleeding disorder, and dengue infection details. Researchers will analyze bleeding severity, replacement therapy needs, and mortality within 14 days of fever onset or hospital discharge. The study also monitors complications like organ failure and infection-related syndromes. This registry aims to improve understanding of dengue infection effects in this high-risk group through systematic data collection and analysis.

International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)